Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Accepted: 17 September 2023
First Online: 26 October 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: Francesco Bonella reports consulting fees and non-financial support from Boehringer Ingelheim, Sanofi, Savara, and Trevi Therapeutics, outside the submitted work. Paolo Spagnolo reports institutional grants, consulting fees and non-financial support from PPM Services; institutional grants, personal fees and non-financial support from Roche and Boehringer Ingelheim; and personal fees from Chiesi, Galapagos, Lupin, Pieris and REDX Pharma, outside the submitted work. Chris Ryerson reports grants from Boehringer Ingelheim, Hoffmann-La Roche and VIDA diagnostics; and personal fees from Boehringer Ingelheim, Hoffmann-La Roche, Veracyte, Pliant Therapeutics, Astra Zeneca, Cipla Ltd and Trevi Therapeutics, outside the submitted work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to conception and drafting of the work and are responsible for all aspects of the manuscript.